CMS
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • CN
  • EN
  • AI Discovery
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Sustainability
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardiovascular-Kidney-Metabolic and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia & the Middle East Business
  • News
    • Company News
    • Partner News
    • Video News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Home
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Sustainability
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia & the Middle East Business
  • News
    • Company News
    • Partner News
  • Investors
    • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • CN
  • EN
×
Ranked in the list of Forbes on the “Best Enterprises Under a Billion”
2022-07-08

Ranked in the list of Forbes on the “Best Enterprises Under a Billion”

Awarded the “Best Listed Company” by Ta Kung Pao

Awarded the “Best Listed Company” by Ta Kung Pao

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Tianjing Kangzhe was awarded the “Top 20 Science and Technology Small Giant Enterprise Certificate (Tianjin Development Zone)” for two consecutive years and “Top 100 Enterprises in Tianjing Development Zone”

Tianjing Kangzhe was awarded the “Top 20 Science and Technology Small Giant Enterprise Certificate (Tianjin Development Zone)” for two consecutive years and “Top 100 Enterprises in Tianjing Development Zone”

Acquired Xili Pharmaceutical and obtained the exclusive sale and marketing rights of DanShenTong in Mainland China

Acquired Xili Pharmaceutical and obtained the exclusive sale and marketing rights of DanShenTong in Mainland China

Acquired assets of Hirudoid and Combizym in Mainland China and/or other countries or regions

Acquired assets of Hirudoid and Combizym in Mainland China and/or other countries or regions

  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Sustainability
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardiovascular-Kidney-Metabolic and Gastroenterology
    • Skin Health Business
    • Ophthalmology
    • Southeast Asia & the Middle East Business
  • News
    • Company News
    • Partner News
    • Video News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Privacy
  • Terms Of Use
All rights reserved by CMS Group 2001-2022 ERP of CMS Group
互联网药品信息服务备案凭证:(粤)-非经营性-粤网药信备字〔2026〕第00023号| 工业和信息化部备案管理系统网站 粤ICP备18157737号| 粤公网安备 44030502003605号